Don’t Be Too Alarmed by the New SCOTUS Antibody Ruling
SCOTUS revisits enablement, but Amgen v. Sanofi probably won’t transform patent law on its own.
written description
-
Read more: Don’t Be Too Alarmed by the New SCOTUS Antibody Ruling -
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: What Does It Mean That Oracle is Partnering with the Trump Administration to Study Unproven COVID-19 Drugs? What Does It Mean That Oracle is Partnering with the Trump Administration to Study Unproven COVID-19 Drugs?
Cross-posted from Written Description, where it originally appeared on March 30, 2020. By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob Sherkow One of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. We decided to unpack this story for ourselves and then…
